Table 3. Phenotypic characteristics... | American Society of Hematology

Table 3.

Phenotypic characteristics differentially expressed by each of the neoplastic B-populations found in B-CLPD with 2 or more B-cell clones

Case no.	Diagnosis	Morphology: no. of major lymphocyte populations	Phenotype of population 1 (% from the total leukocytes; compatible diagnosis)	Phenotype of population 2 (% from the total leukocytes; compatible diagnosis)
1	typCLL	3	CD19⁺ FMC7^- CD5⁺ CD22^- CD23^+d CD11c^-/+het slg^- (28%; B-CLL)	CD19⁺⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD11c^- k⁺ (6.7%; LPL)
2	typCLL	2	CD19⁺ FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25^+d (39%; B-CLL)	CD19⁺⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- (6%; SMZL)
3	typCLL	2	FSC/SSC^lo CD25^+d slg^- (25%; B-CLL)	FSC/SSC^int CD25⁺ λ^+d (29%; B-CLL)
4	typCLL	3	CD23⁺ κ^+d (50%; B-CLL)	CD23^- λ⁺ (9%; MALT)
5	typCLL	1	κ^+d (34%; B-CLL)	λ⁺ (13%; B-CLL)
6	typCLL	2	FSC/SSC^lo FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25⁺ CD11c^+het slg^- (15%; B-CLL)	FSC/SSC^int FMC7⁺ CD5⁺⁺ CD22⁺ CD23^- CD25^- CD11c^- λ^+d (12%; MCL)
7	typCLL	2	FSC/SSC^lo CD19^+d FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25^+d CD11c^- λ^+d (24%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺⁺ CD23^- CD25^- CD11c⁺⁺ κ^+d (22%; SMZL)
8	typCLL	1	FSC/SSC^lo CD5⁺ CD11c^- λ^+d (9%; B-CLL)	FSC/SSC^int CD5⁺⁺ CD11c⁺ κ^+d (10%; B-CLL)
9	typCLL	1	κ⁺ (25%; B-CLL)	λ⁺ (8%; B-CLL)
10	typCLL	2	CD5⁺⁺ κ^+d (63%; B-CLL)	CD5⁺ λ⁺ (2%; B-CLL)
11	typCLL	2	κ^+d (72%; B-CLL)	λ⁺ (7%; B-CLL)
12	typCLL	NA	κ⁺ (2.4%; B-CLL)	λ⁺ (38%; B-CLL)
13	typCLL	2	FSC/SSC^lo CD5⁺⁺ CD25^- CD11c^+d (36%; B-CLL)	FSC/SSC^int CD5⁺⁺⁺ CD25^+d CC11c⁺ (37%; B-CLL)
14	typCLL	2	CD5^- CD11c^- (31%; B-CLL)	CD5⁺ CD11c⁺ (7%; B-CLL)
15	typCLL	2	λ⁺ (48%; B-CLL)	κ⁺ (6%; B-CLL)
16	typCLL	3	CD19⁺ FMC7^- (18%; B-CLL)	CD19⁺⁺ FMC7⁺ (44%; B-CLL)
17	typCLL	NA	λ^+d (38%; B-CLL)	κ^+d (8%; B-CLL)
18	typCLL	NA	FSC/SSC^lo CD5⁺⁺ CD25^+d λ⁺ (39%; B-CLL)	FSC/SSC^int CD5⁺⁺⁺ CD25⁺ κ^+d (16%; B-CLL)
19	typCLL	NA	κ⁺ (8%; B-CLL)	λ⁺ (20%; B-CLL)
20	typCLL	NA	FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- κ⁺⁺ (9.7%; LPL)	FMC7^- CD5⁺⁺ CD22^+d CD23⁺⁺ CD25⁺ λ⁺⁺ (55%; B-CLL)
21	typCLL	2	FSC/SSC^lo CD19⁺ FMC7^- CD5⁺⁺ CD22^+d CD23⁺ CD25⁺ CD11c^-/+het λ⁺ (36%; B-CLL)	FSC/SSC^int CD19⁺⁺ FMC7⁺ CD5⁺ CD22⁺ CD23^- CD25^- CD11c⁺ κ⁺⁺ (8%; MCL)
22	typCLL	2	FMC7^- CD5⁺⁺⁺ CD22^+d CD23⁺ κ⁺ (28%; B-CLL)	FMC7⁺⁺ CD5⁺⁺ CD22⁺ CD23^- κ⁺⁺ (8.5%; MCL)
23	typCLL	NA	FSC/SSC^lo CD19⁺ CD5⁺ CD22^- CD23^+d CD25^- λ^+d (10%; B-CLL)	FSC/SSC^int CD19⁺⁺ CD5⁺⁺ CD22^+d CD23⁺ CD25⁺ κ^+d (45%; B-CLL)
24	typCLL	NA	κ⁺ (31%; B-CLL)	λ⁺ (42%; B-CLL)
25	atypCLL	2	FSC/SSC^lo CD19^+d FMC7^- CD5⁺ CD23⁺ slg^- (3%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD23^+d κ⁺ (9%; LPL)
26	atypCLL	2	FSC/SSC^lo CD19⁺ FMC7^+d CD5⁺ CD23⁺ CD25⁺ κ⁺ (23.2%; B-CLL)	FSC/SSC^int CD19⁺⁺ FMC7⁺⁺ CD5^+d CD23^+d CD25^- κ⁺⁺ (62.8%; B-CLL)
27	atypCLL	≥3	CD5^- CD23^- CD11c^- λ⁺ (7.4%; LPL)	CD5⁺ CD23⁺ CD11c⁺⁺ κ^+d (2.3%; B-CLL)
28	atypCLL	NA	FSC/SSC^lo CD19^+d FMC7^+d CD5⁺⁺ CD22^+d CD23⁺⁺ CD25⁺⁺ κ⁺ (10%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5⁺ CD22⁺ CD23⁺ CD25⁺ λ⁺⁺ (15%; MALT)
29	atypCLL	2	CD19⁺ FMC7^- CD5^+d CD22^+d CD23⁺ κ^+d (60%; B-CLL)	CD19⁺⁺ FMC7⁺ CD5^- CD22⁺ CD23^- λ⁺ (7%; FL)
30	atypCLL	2	CD5⁺⁺ κ^+d (16%; B-CLL)	CD5⁺ κ⁺ (42%; MCL)
31	atypCLL	2	λ⁺ (56%; B-CLL)	κ^+d (8%; B-CLL)
32	atypCLL	3	FSC/SSC^lo CD19^+d FMC7^- CD5⁺ CD22^+d CD103^- CD11c^- slg^- (3.8%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺ CD103⁺ CD11c⁺ λ⁺ (25.4%; HCL)
33	atypCLL	NA	κ⁺ (4%; MALT)	λ⁺ (20%; MALT)
34	HCL	2	FSC/SSC^lo CD103^- CD25^- CD11c⁺⁺ λ⁺ (3.7%; SMZL)	FSC/SSC^int CD103⁺ CD25⁺ CD11c⁺⁺⁺ κ⁺ (4.5%; HCL)
35	HCL	NA	FSC/SSC^lo CD19^+d FMC7^- CD5⁺ CD22^+d CD23⁺ CD103^- CD25^+d CD11c^-/+het κ^+d (0.8%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD103⁺ CD25^- CD11c⁺⁺ κ⁺ (1.1%; HCL)
36	HCL	1	CD19⁺ FMC7^-/+het CD11c^+d κ⁺ (30.5%; MALT)	CD19⁺⁺ FMC7⁺⁺⁺ CD11c⁺⁺ κ^+d (6.3%; HCLv)
37	HCL	2	CD103⁺ (22%; SMZL)	CD103⁺⁺ (5%; HCL)
38	LPL	NA	CD19⁺ FMC7⁺ CD5⁺ CD22^+d CD23⁺ CD25⁺⁺ CD11c^- (6.5%; B-CLL)	CD19⁺⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- CD11c^-/+het (38%; LPL)
39	LPL	NA	λ^+d (21%; B-CLL)	λ⁺⁺ (0.6%; LPL)
40	LPL	3	FSC/SSC^lo FMC7^- CD5⁺ κ⁺⁺ (1.5%; MCL)	FSC/SSC^int FMC7⁺ CD5^- λ⁺⁺ (4.7%; LCL)
41	LPL	2	λ⁺ (46%; LPL)	κ⁺ (6%; LPL)
42	SMZL	2	FSC/SSC^lo CD19^+d FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25⁺ slg^- (0.6%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- λ^+d (3.7%; SMZL)
43	SMZL	2	CD5⁺ (60%; MALT)	CD5^- (6%; SMZL)
44	SMZL	2	κ⁺⁺ (29%; SMZL)	λ⁺⁺ (25%; SMZL)
45	FL	NA	CD5⁺ CD22^+d CD23^- κ⁺⁺ (57%; MCL)	CD5^- CD22⁺ CD23^-/+het κ⁺ (9%; FL)
46	FL	2	FSC/SSC^lo CD5^- CD23^- CD103^- CD25^- CD11c^- λ⁺ (6%; FL)	FSC/SSC^int CD5⁺ CD23⁺ CD103⁺ CD25⁺ CD11c⁺⁺⁺ κ⁺ (47%; LCL)
47	FL	NA	κ⁺ (4.5%; FL)	λ⁺ (2.2%; FL)
48	MCL	2	FSC/SSC^lo CD19⁺ FMC7⁺ CD22⁺ CD23⁺ κ⁺ (12%; MALT)	FSC/SSC^int CD19^+d FMC7⁺⁺ CD22^+d CD23^- λ⁺ (66%; MCL)
49	MCL	NA	FSC/SSC^lo FMC7^+hom CD5^+d κ^+d (11%; MCL)	FSC/SSC^int FMC7^+het CD5⁺ κ⁺ (22%; MCL)
50	LCL	NA	FSC/SSC^lo CD22^+d CD10^- CD11c^- κ^+d (23%; B-CLL)	FSC/SSC^int CD22⁺ CD10^+d CD11c⁺ slg^- (12%; LCL)
51	LCL	2	FSC/SSC^lo CD19^+d FMC7^- CD22^- CD25^- CD11c^- κ^+d (60%; LPL)	FSC/SSC^int CD19⁺ FMC7^+het CD22^+d CD25^+d CD11c^+d κ⁺ (14%; LCL)
52	Unclassifiable	2	FSC/SSC^lo FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25⁺ λ⁺ (42%; B-CLL)	FSC/SSC^int FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- κ⁺ (36%; SMZL)
53	Unclassifiable	2	CD5^- CD23^- λ⁺ (18%; LPL)	CD5⁺⁺ CD23⁺ κ^+d (3.5%; B-CLL)

Case no.	Diagnosis	Morphology: no. of major lymphocyte populations	Phenotype of population 1 (% from the total leukocytes; compatible diagnosis)	Phenotype of population 2 (% from the total leukocytes; compatible diagnosis)
1	typCLL	3	CD19⁺ FMC7^- CD5⁺ CD22^- CD23^+d CD11c^-/+het slg^- (28%; B-CLL)	CD19⁺⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD11c^- k⁺ (6.7%; LPL)
2	typCLL	2	CD19⁺ FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25^+d (39%; B-CLL)	CD19⁺⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- (6%; SMZL)
3	typCLL	2	FSC/SSC^lo CD25^+d slg^- (25%; B-CLL)	FSC/SSC^int CD25⁺ λ^+d (29%; B-CLL)
4	typCLL	3	CD23⁺ κ^+d (50%; B-CLL)	CD23^- λ⁺ (9%; MALT)
5	typCLL	1	κ^+d (34%; B-CLL)	λ⁺ (13%; B-CLL)
6	typCLL	2	FSC/SSC^lo FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25⁺ CD11c^+het slg^- (15%; B-CLL)	FSC/SSC^int FMC7⁺ CD5⁺⁺ CD22⁺ CD23^- CD25^- CD11c^- λ^+d (12%; MCL)
7	typCLL	2	FSC/SSC^lo CD19^+d FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25^+d CD11c^- λ^+d (24%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺⁺ CD23^- CD25^- CD11c⁺⁺ κ^+d (22%; SMZL)
8	typCLL	1	FSC/SSC^lo CD5⁺ CD11c^- λ^+d (9%; B-CLL)	FSC/SSC^int CD5⁺⁺ CD11c⁺ κ^+d (10%; B-CLL)
9	typCLL	1	κ⁺ (25%; B-CLL)	λ⁺ (8%; B-CLL)
10	typCLL	2	CD5⁺⁺ κ^+d (63%; B-CLL)	CD5⁺ λ⁺ (2%; B-CLL)
11	typCLL	2	κ^+d (72%; B-CLL)	λ⁺ (7%; B-CLL)
12	typCLL	NA	κ⁺ (2.4%; B-CLL)	λ⁺ (38%; B-CLL)
13	typCLL	2	FSC/SSC^lo CD5⁺⁺ CD25^- CD11c^+d (36%; B-CLL)	FSC/SSC^int CD5⁺⁺⁺ CD25^+d CC11c⁺ (37%; B-CLL)
14	typCLL	2	CD5^- CD11c^- (31%; B-CLL)	CD5⁺ CD11c⁺ (7%; B-CLL)
15	typCLL	2	λ⁺ (48%; B-CLL)	κ⁺ (6%; B-CLL)
16	typCLL	3	CD19⁺ FMC7^- (18%; B-CLL)	CD19⁺⁺ FMC7⁺ (44%; B-CLL)
17	typCLL	NA	λ^+d (38%; B-CLL)	κ^+d (8%; B-CLL)
18	typCLL	NA	FSC/SSC^lo CD5⁺⁺ CD25^+d λ⁺ (39%; B-CLL)	FSC/SSC^int CD5⁺⁺⁺ CD25⁺ κ^+d (16%; B-CLL)
19	typCLL	NA	κ⁺ (8%; B-CLL)	λ⁺ (20%; B-CLL)
20	typCLL	NA	FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- κ⁺⁺ (9.7%; LPL)	FMC7^- CD5⁺⁺ CD22^+d CD23⁺⁺ CD25⁺ λ⁺⁺ (55%; B-CLL)
21	typCLL	2	FSC/SSC^lo CD19⁺ FMC7^- CD5⁺⁺ CD22^+d CD23⁺ CD25⁺ CD11c^-/+het λ⁺ (36%; B-CLL)	FSC/SSC^int CD19⁺⁺ FMC7⁺ CD5⁺ CD22⁺ CD23^- CD25^- CD11c⁺ κ⁺⁺ (8%; MCL)
22	typCLL	2	FMC7^- CD5⁺⁺⁺ CD22^+d CD23⁺ κ⁺ (28%; B-CLL)	FMC7⁺⁺ CD5⁺⁺ CD22⁺ CD23^- κ⁺⁺ (8.5%; MCL)
23	typCLL	NA	FSC/SSC^lo CD19⁺ CD5⁺ CD22^- CD23^+d CD25^- λ^+d (10%; B-CLL)	FSC/SSC^int CD19⁺⁺ CD5⁺⁺ CD22^+d CD23⁺ CD25⁺ κ^+d (45%; B-CLL)
24	typCLL	NA	κ⁺ (31%; B-CLL)	λ⁺ (42%; B-CLL)
25	atypCLL	2	FSC/SSC^lo CD19^+d FMC7^- CD5⁺ CD23⁺ slg^- (3%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD23^+d κ⁺ (9%; LPL)
26	atypCLL	2	FSC/SSC^lo CD19⁺ FMC7^+d CD5⁺ CD23⁺ CD25⁺ κ⁺ (23.2%; B-CLL)	FSC/SSC^int CD19⁺⁺ FMC7⁺⁺ CD5^+d CD23^+d CD25^- κ⁺⁺ (62.8%; B-CLL)
27	atypCLL	≥3	CD5^- CD23^- CD11c^- λ⁺ (7.4%; LPL)	CD5⁺ CD23⁺ CD11c⁺⁺ κ^+d (2.3%; B-CLL)
28	atypCLL	NA	FSC/SSC^lo CD19^+d FMC7^+d CD5⁺⁺ CD22^+d CD23⁺⁺ CD25⁺⁺ κ⁺ (10%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5⁺ CD22⁺ CD23⁺ CD25⁺ λ⁺⁺ (15%; MALT)
29	atypCLL	2	CD19⁺ FMC7^- CD5^+d CD22^+d CD23⁺ κ^+d (60%; B-CLL)	CD19⁺⁺ FMC7⁺ CD5^- CD22⁺ CD23^- λ⁺ (7%; FL)
30	atypCLL	2	CD5⁺⁺ κ^+d (16%; B-CLL)	CD5⁺ κ⁺ (42%; MCL)
31	atypCLL	2	λ⁺ (56%; B-CLL)	κ^+d (8%; B-CLL)
32	atypCLL	3	FSC/SSC^lo CD19^+d FMC7^- CD5⁺ CD22^+d CD103^- CD11c^- slg^- (3.8%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺ CD103⁺ CD11c⁺ λ⁺ (25.4%; HCL)
33	atypCLL	NA	κ⁺ (4%; MALT)	λ⁺ (20%; MALT)
34	HCL	2	FSC/SSC^lo CD103^- CD25^- CD11c⁺⁺ λ⁺ (3.7%; SMZL)	FSC/SSC^int CD103⁺ CD25⁺ CD11c⁺⁺⁺ κ⁺ (4.5%; HCL)
35	HCL	NA	FSC/SSC^lo CD19^+d FMC7^- CD5⁺ CD22^+d CD23⁺ CD103^- CD25^+d CD11c^-/+het κ^+d (0.8%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD103⁺ CD25^- CD11c⁺⁺ κ⁺ (1.1%; HCL)
36	HCL	1	CD19⁺ FMC7^-/+het CD11c^+d κ⁺ (30.5%; MALT)	CD19⁺⁺ FMC7⁺⁺⁺ CD11c⁺⁺ κ^+d (6.3%; HCLv)
37	HCL	2	CD103⁺ (22%; SMZL)	CD103⁺⁺ (5%; HCL)
38	LPL	NA	CD19⁺ FMC7⁺ CD5⁺ CD22^+d CD23⁺ CD25⁺⁺ CD11c^- (6.5%; B-CLL)	CD19⁺⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- CD11c^-/+het (38%; LPL)
39	LPL	NA	λ^+d (21%; B-CLL)	λ⁺⁺ (0.6%; LPL)
40	LPL	3	FSC/SSC^lo FMC7^- CD5⁺ κ⁺⁺ (1.5%; MCL)	FSC/SSC^int FMC7⁺ CD5^- λ⁺⁺ (4.7%; LCL)
41	LPL	2	λ⁺ (46%; LPL)	κ⁺ (6%; LPL)
42	SMZL	2	FSC/SSC^lo CD19^+d FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25⁺ slg^- (0.6%; B-CLL)	FSC/SSC^int CD19⁺ FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- λ^+d (3.7%; SMZL)
43	SMZL	2	CD5⁺ (60%; MALT)	CD5^- (6%; SMZL)
44	SMZL	2	κ⁺⁺ (29%; SMZL)	λ⁺⁺ (25%; SMZL)
45	FL	NA	CD5⁺ CD22^+d CD23^- κ⁺⁺ (57%; MCL)	CD5^- CD22⁺ CD23^-/+het κ⁺ (9%; FL)
46	FL	2	FSC/SSC^lo CD5^- CD23^- CD103^- CD25^- CD11c^- λ⁺ (6%; FL)	FSC/SSC^int CD5⁺ CD23⁺ CD103⁺ CD25⁺ CD11c⁺⁺⁺ κ⁺ (47%; LCL)
47	FL	NA	κ⁺ (4.5%; FL)	λ⁺ (2.2%; FL)
48	MCL	2	FSC/SSC^lo CD19⁺ FMC7⁺ CD22⁺ CD23⁺ κ⁺ (12%; MALT)	FSC/SSC^int CD19^+d FMC7⁺⁺ CD22^+d CD23^- λ⁺ (66%; MCL)
49	MCL	NA	FSC/SSC^lo FMC7^+hom CD5^+d κ^+d (11%; MCL)	FSC/SSC^int FMC7^+het CD5⁺ κ⁺ (22%; MCL)
50	LCL	NA	FSC/SSC^lo CD22^+d CD10^- CD11c^- κ^+d (23%; B-CLL)	FSC/SSC^int CD22⁺ CD10^+d CD11c⁺ slg^- (12%; LCL)
51	LCL	2	FSC/SSC^lo CD19^+d FMC7^- CD22^- CD25^- CD11c^- κ^+d (60%; LPL)	FSC/SSC^int CD19⁺ FMC7^+het CD22^+d CD25^+d CD11c^+d κ⁺ (14%; LCL)
52	Unclassifiable	2	FSC/SSC^lo FMC7^+d CD5⁺ CD22^+d CD23⁺ CD25⁺ λ⁺ (42%; B-CLL)	FSC/SSC^int FMC7⁺⁺ CD5^- CD22⁺ CD23^- CD25^- κ⁺ (36%; SMZL)
53	Unclassifiable	2	CD5^- CD23^- λ⁺ (18%; LPL)	CD5⁺⁺ CD23⁺ κ^+d (3.5%; B-CLL)

+ indicates antigen expression at normal levels; -, absence of expression; het, heterogeneous antigen expression; ++, strong antigen expression; d, dim antigen expression; SSClo, low scatter; SSCint, intermediate scatter; +++, very strong antigen expression; HCLv, HCL variant; and hom, homogeneous antigen expression. Other abbreviations are explained in Table 1.

View Large

This Feature Is Available To Subscribers Only